- Home
- IMA vs CBAT Comparison
IMA vs CBAT Comparison
Compare IMA & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMA
- CBAT
- Stock Information
- Founded
- IMA 2019
- CBAT 1999
- Country
- IMA United States
- CBAT China
- Employees
- IMA N/A
- CBAT N/A
- Industry
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- CBAT Industrial Machinery/Components
- Sector
- IMA Health Care
- CBAT Miscellaneous
- Exchange
- IMA Nasdaq
- CBAT Nasdaq
- Market Cap
- IMA 92.2M
- CBAT 90.4M
- IPO Year
- IMA N/A
- CBAT N/A
- Fundamental
- Price
- IMA $8.23
- CBAT $0.90
- Analyst Decision
- IMA Buy
- CBAT
- Analyst Count
- IMA 1
- CBAT 0
- Target Price
- IMA $30.00
- CBAT N/A
- AVG Volume (30 Days)
- IMA 68.3K
- CBAT 203.0K
- Earning Date
- IMA 11-12-2025
- CBAT 11-10-2025
- Dividend Yield
- IMA N/A
- CBAT N/A
- EPS Growth
- IMA N/A
- CBAT N/A
- EPS
- IMA N/A
- CBAT N/A
- Revenue
- IMA $800,000.00
- CBAT $161,757,685.00
- Revenue This Year
- IMA N/A
- CBAT N/A
- Revenue Next Year
- IMA N/A
- CBAT $60.02
- P/E Ratio
- IMA N/A
- CBAT N/A
- Revenue Growth
- IMA N/A
- CBAT N/A
- 52 Week Low
- IMA $7.24
- CBAT $0.57
- 52 Week High
- IMA $23.28
- CBAT $1.28
- Technical
- Relative Strength Index (RSI)
- IMA N/A
- CBAT 42.84
- Support Level
- IMA N/A
- CBAT $0.89
- Resistance Level
- IMA N/A
- CBAT $0.95
- Average True Range (ATR)
- IMA 0.00
- CBAT 0.04
- MACD
- IMA 0.00
- CBAT -0.00
- Stochastic Oscillator
- IMA 0.00
- CBAT 27.02
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.